Preserved platelet function during cardiopulmonary bypass with aprotinin in dual antiplatelet therapy. - Aprotinin study

Isala Klinieken0 个研究点目标入组 58 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1. Positive pregnancy test, pregnancy or lactation.
•2. Women of child-bearing age not using a medically approved method of
•contraception during the study.
•3. Undergoing an emergency operation.
•4. Proof or suspicion of a congenital or acquired coagulation disorder (e.g.
•VWD or via severe liver disease).
•5. Apoplexy in the 2 months preceding study surgery.
•6. Manifest venous or arterial thrombosis.
•7. Medication:
•o Tirofiban administration in the 2 days preceding surgery.
•o INR >1.4 if on coumadines.
•8. Participation in another clinical study in the 4 weeks preceding this study.
•9. Having received aprotinin in the last 2 months, in the absence of a IgG
•antibody test
•10. Renal dysfunction, defined as eGFR <45 (mL/min/1.73m2)
•11. Sensitivity to any of the components of study medication.
•12. Any indication that the restrictions or procedures of the study may not be
•adhered to (e.g. an uncooperative attitude).
•13. Any indication that the study restrictions, procedures, or consequences
•therein have not been considered or understood, such that informed consent
•cannot be convincingly given.
•14. Multiple morbidities, with a notably constrained remaining length of life.

发起方

Isala Klinieken